"Nuestra prioridad es la atención humanizada del paciente oncológico y nuestro objetivo es lograr la comprensión integral de las personas que atendemos."

During the past decade, Instituto de Oncología de Rosario conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 20 clinical trials were completed, i.e. on average, 71.4% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 8 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto de Oncología de Rosario" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Pfizer" with 10 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 3 trials sponsored and "Merck Sharp & Dohme LLC" with 3 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Oncología de Rosario" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "NSABP Foundation Inc" with 3 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator and "Bristol-Myers Squibb" with 2 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Instituto de Oncología de Rosario" are "Breast Cancer" (4 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Metastatic Breast Cancer" (4 trials), "Melanoma" (3 trials) and "Breast Neoplasms" (2 trials). Many other conditions were trialed in "Instituto de Oncología de Rosario" in a lesser frequency.

Most popular intervention types in "Instituto de Oncología de Rosario" are "Drug" (42 trials), "Biological" (7 trials), "Radiation" (3 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Paclitaxel" (5 trials), "Atezolizumab" (4 trials), "Capecitabine" (4 trials) and "Cisplatin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Instituto de Oncología de Rosario" are 36 trials for "All" genders, 6 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto de Oncología de Rosario". undefined are not yet recruiting, 9 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Instituto de Oncología de Rosario, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto de Oncología de Rosario, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".